Search alternatives:
significantly linear » significant linear (Expand Search), significantly lower (Expand Search), significantly longer (Expand Search)
linear decrease » linear increase (Expand Search)
better decrease » greater decrease (Expand Search), between decreased (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
significantly linear » significant linear (Expand Search), significantly lower (Expand Search), significantly longer (Expand Search)
linear decrease » linear increase (Expand Search)
better decrease » greater decrease (Expand Search), between decreased (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
-
2141
Data Sheet 1_Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study.docx
Published 2025“…IgG and IgM levels remained above the lower limits of normal in most participants. sNfL levels decreased, remaining reduced by M24. Significant reductions in the annualized combined unique active lesion count occurred from M2 onwards. …”
-
2142
Data Sheet 2_Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study.csv
Published 2025“…IgG and IgM levels remained above the lower limits of normal in most participants. sNfL levels decreased, remaining reduced by M24. Significant reductions in the annualized combined unique active lesion count occurred from M2 onwards. …”
-
2143
Table 1_COVID-19 pandemic increased ESKAPEEc bloodstream infections and amplified carbapenem resistance in Chinese children: a multicenter surveillance study (2016–2023).xls
Published 2025“…Temporal variations and linear trends were evaluated using chi-square or Fisher’s exact tests.…”
-
2144
Table 1_GLP1 receptor agonists and SGLT2 inhibitors for the prevention or delay of type 2 diabetes mellitus onset: a systematic review and meta-analysis.docx
Published 2025“…Finally, no significant change in fasting insulin levels was noticed with an overall SMD of -1.74 (95% CI: [-6.84, 3.37]), which was also not statistically significant (p-value: 0.55). …”
-
2145
<b>Regional asymmetries in dissolved organic carbon response to nitrogen addition rather than soil organic carbon and microbial biomass carbon</b>
Published 2024“…The effect size of soil DOC decreased linearly with that of MBC to SOC ratio in humid regions, while it increased linearly in non-humid regions. …”
-
2146
Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2147
Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2148
Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2149
Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2150
Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2151
Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2152
Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2153
Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2154
Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2155
Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2156
Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2157
Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
Published 2025“…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
-
2158
The Effect of Chronic Stress on Apoptosis Regulation and Oncogenesis Evolution: A Theoretical Approach.
Published 2025“…The following presentation describes these pathways in depth, provides clinical data, and conducts biochemical investigations, all of which contribute to a better understanding of the link between mental health and cellular malfunction.…”
-
2159
Table 1_Correlation between lactate/albumin ratio and 28-day mortality in sepsis-associated acute kidney injury patients.docx
Published 2025“…The Kaplan–Meier curves showed that participants having elevated LAR exhibited significantly decreased survival rates. Cox proportional hazards models showed that higher LAR was related to higher 28-day death rate in SA-AKI patients (HR: 1.224, 95% CI: 1.160–1.291, p < 0.001). …”
-
2160
Image 1_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.tif
Published 2025“…Significant heterogeneity was detected in the pooled analysis and meta-regression analysis suggested that participants’ age and the prevalence of diabetes significantly accounted for the heterogeneity.…”